Literature DB >> 6457546

[Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)].

M Thibault, B Koumaré, C J Soussy, J Duval.   

Abstract

Authors describe structure-activity relationships in quinolone group and report a study of the antibacterial activity of two new compounds: pefloxacin and its demethyl derivative, AM-715. These two products take place in the field of researches carried out for extending indications of this group of antimicrobial agents by obtaining derivatives more active, with broader spectrum, less biotransformed and susceptible to be used in general infections and not only in urinary tract infections.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6457546

Source DB:  PubMed          Journal:  Ann Microbiol (Paris)        ISSN： 0300-5410


  9 in total

1.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Evaluation of pefloxacin in experimental Escherichia coli meningitis.

Authors:  A M Shibl; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Pharmacokinetics of pefloxacin in renal insufficiency.

Authors:  G Montay; C Jacquot; J Bariety; R Cunci
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

8.  Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.

Authors:  F M Gordin; C J Hackbarth; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).

Authors:  J B Cornett; R B Wagner; R A Dobson; M P Wentland; D M Bailey
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.